HSPD1 encodes HSP60, a mitochondrial chaperonin that functions as a heptameric ring component working together with the co-chaperonin HSP10 to facilitate proper folding of proteins imported into the mitochondrial matrix and to prevent misfolding under stress conditions. The chaperonin complex binds unfolded substrate proteins within its inner cavity, allowing them to fold undisturbed before ATP hydrolysis releases the folded product. HSPD1 is implicated in multiple disease contexts. In rheumatoid arthritis, synovial fibroblasts overexpress HSPD1, and anti-HSP60 autoantibodies derived from local B cells exhibit pathogenic properties 1; notably, HSP60 gene expression reduction following B cell-depleting therapy with rituximab correlates with treatment response. In cardiomyopathy, HSPD1 mutations disrupt mitochondrial protein homeostasis, impairing ATP production and cardiac function 2. Recent evidence suggests HSPD1 functions in mitophagy pathways that regulate cancer cell survival 3, and analysis of esophageal cancer identifies HSPD1 as a prognostic biomarker 4. These findings position HSPD1 as both a target for autoimmune-mediated pathology and a mediator of mitochondrial quality control relevant to cancer progression and metabolic disease.